Year: 2025
Type: article
Abstract: The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).
Source: Cardiovascular Diabetology
Authors: Oliver Schnell, Jaime Almandoz, Lisa Anderson, Katharine Barnard-Kelly, Tadej Battelino, Matthias Blüher, Luca Busetto, Doina Catrinou, Antonio Ceriello, Xavier Cos, Thomas Danne, Colin M. Dayan, Stefano Del Prato, Beatriz Fernández-Fernández, Paola Fioretto, Thomas Forst, James R. Gavin, Francesco Giorgino, Per-Henrik Groop, Igor A. Harsch, Hiddo J. L. Heerspink, Lutz Heinemann, Mahmoud Ibrahim, Michel Jadoul, Sarah Jarvis, Linong Ji, Naresh Kanumilli, Mikhail Kosiborod, Ulf Landmesser, Sofia Macieira, Boris Mankovsky, Nikolaus Marx, Chantal Mathieu, Barbara McGowan, Tatjana Milenkovic, Othmar Moser, Dirk Müller-Wieland, Nikolaos Papanas, Dipesh C. Patel, Andreas F. H. Pfeiffer, Dario Rahelić, Helena W. Rodbard, Lars Rydén, Elke Schaeffner, C. Wendy Spearman, Alin Stirban, Frank Tacke, Pinar Topsever, Luc Van Gaal, Eberhard Standl
Institutions: Helmholtz Munich, The University of Texas Southwestern Medical Center, St George's, University of London, St George’s University Hospitals NHS Foundation Trust, Southern Health NHS Foundation Trust, University of Ljubljana, Ljubljana University Medical Centre, University Hospital Leipzig, Leipzig University, University of Padua, Ovidius University, MultiMedica, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Universidade Nova de Lisboa, Cardiff University, Scuola Superiore Sant'Anna, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Clinical Research Services, Emory University, University of Bari Aldo Moro, University of Helsinki, Baker Heart and Diabetes Institute, Helsinki University Hospital, Folkhälsans Forskningscentrum, Monash University, University Medical Center Groningen, University of Groningen, Cliniques Universitaires Saint-Luc, UCLouvain, Peking University People's Hospital, Manchester University NHS Foundation Trust, Saint Luke's Hospital, University of Missouri–Kansas City, Charité - Universitätsmedizin Berlin, Shupyk National Healthcare University of Ukraine, Universitätsklinikum Aachen, RWTH Aachen University, KU Leuven, St Thomas' Hospital, King's College London, Ss. Cyril and Methodius University in Skopje, Medical University of Graz, University of Bayreuth, Democritus University of Thrace, The Royal Free Hospital, University College London, German Center for Diabetes Research, Klinička bolnica Merkur, Karolinska Institutet, University of Cape Town, Acıbadem University, Antwerp University Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,290
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Amarin Corporation, Insulet Corporation, MannKind Corporation, Cytokinetics, Dexcom, Pacira BioSciences, European Foundation for the Study of Diabetes, Daiichi-Sankyo, KU Leuven, Novo Nordisk, Astellas Pharma, Vifor Pharma, European Association for the Study of Diabetes, Servier, Roche Diabetes Care, Lilly Deutschland, Esperion Therapeutics, Wörwag Pharma, Merck Sharp and Dohme, Abbott Diabetes Care, Janssen Pharmaceuticals
OpenAlex ID: W4410025824